For: | Walia D, Saraya A, Gunjan D. COVID-19 in patients with pre-existing chronic liver disease – predictors of outcomes. World J Virol 2023; 12(1): 30-43 [PMID: 36743659 DOI: 10.5501/wjv.v12.i1.30] |
---|---|
URL: | https://www.wjgnet.com/2220-3249/full/v12/i1/30.htm |
Number | Citing Articles |
1 |
Pablo Amend, Patricia Mester, Stephan Schmid, Martina Müller, Christa Buechler, Vlad Pavel. Plasma Chemerin Is Induced in Critically Ill Patients with Gram-Positive Infections. Biomedicines 2023; 11(7): 1779 doi: 10.3390/biomedicines11071779
|
2 |
Agata Michalak, Tomasz Lach, Karolina Szczygieł, Halina Cichoż-Lach. COVID-19, Possible Hepatic Pathways and Alcohol Abuse—What Do We Know up to 2023?. International Journal of Molecular Sciences 2024; 25(4): 2212 doi: 10.3390/ijms25042212
|
3 |
Shahrzad Shoraka, Seyed Reza Mohebbi, Seyed Masoud Hosseini, Amir Ghaemi, Mohammad Reza Zali. SARS-CoV-2 and chronic hepatitis B: Focusing on the possible consequences of co-infection. Journal of Clinical Virology Plus 2023; 3(4): 100167 doi: 10.1016/j.jcvp.2023.100167
|
4 |
Nouhoum Bouare, Jean Delwaide. Interleukin-mediated therapies in liver diseases and comorbidity effects. World Journal of Hepatology 2024; 16(7): 980-989 doi: 10.4254/wjh.v16.i7.980
|
5 |
Vlad Pavel, Pablo Amend, Niklas Schmidtner, Alexander Utrata, Charlotte Birner, Stephan Schmid, Sabrina Krautbauer, Martina Müller, Patricia Mester, Christa Buechler. Chemerin Levels in COVID-19 Are More Affected by Underlying Diseases than by the Virus Infection Itself. Biomedicines 2024; 12(9): 2099 doi: 10.3390/biomedicines12092099
|